Status:
WITHDRAWN
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Lead Sponsor:
Jennifer Amengual
Collaborating Sponsors:
Columbia University
Conditions:
Lymphoma, T-Cell, Peripheral
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
This study employs a 1:1 randomization of patients to receive romidepsin alone verses romidepsin plus pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ...
Detailed Description
Over the past 8 years, 3 new classes of drugs have been approved for the group of diseases recognized as peripheral T-cell lymphoma (PTCL). The novel anti-folate pralatrexate was the first drug approv...
Eligibility Criteria
Inclusion
- Patients must have histologically confirmed relapsed or refractory aggressive peripheral T-cell lymphoma as defined by 2016 World Health Organization (WHO) criteria (excluding nasal natural killer t-cell (NK-T) and blastic natural killer (NK))
- Patients are required to have no more than 5 lines of prior therapy (with cytoreductive therapy followed by autologous stem cell transplant counting as one line of therapy. Patients are eligible if they have relapsed after prior autologous or allogeneic stem cell transplant
- Measurable Disease
- Age \>18 years
- Eastern Cooperative Oncology Group (ECOG) performance status \<2
- Patients must have adequate organ and marrow function
- Adequate contraception
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Prior Therapy
- Prior exposure to pralatrexate or a histone deacetylase inhibitor (romidepsin, chidamide, belinostat, or vonrinostat)
- Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
- Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs.
- No other concurrent investigational agents are allowed.
- Central nervous system metastases, including lymphomatous meningitis
- Uncontrolled intercurrent illness
- Pregnant women
- Nursing women
- Current malignancy or history of a prior malignancy
- Patient known to be Human Immunodeficiency Virus (HIV)-positive
- Active Hepatitis A, Hepatitis B, or Hepatitis C infection
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03355768
Start Date
September 1 2018
End Date
November 1 2018
Last Update
December 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.